Open Label Study of the Safety and Efficacy of FDC Zepatier (Elbasvir+Grazoprevir +/- Ribavirin)Administered in a Community Based Setting to HCV Infected G1/4 Treatment naïve Patients on Stable Opiate Substitution Therapy With Cirrhotic and Non-cirrhotic Liver Disease
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Sep 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Aug 2017 Planned End Date changed from 1 May 2019 to 1 Jan 2019.
- 29 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.
- 29 Aug 2017 Planned initiation date changed from 12 Jun 2017 to 23 Oct 2017.